TY  - CONF
AU  - Valladares-Ayerbes, M.
AU  - Safont, M. J.
AU  - Gonzalez-Flores, E.
AU  - Garcia-Alfonso, P.
AU  - Aranda Aguilar, E.
AU  - Lopez-Munoz, A. M.
AU  - Cirera-Nogueras, L.
AU  - Falco-Ferrer, E. 
AU  - Rodriguez-Salas, N
AU  - Aparicio, J.
AU  - Llanos, M.
AU  - Castillo-Trujillo, O.A.
AU  - Pimentel-Caceres, P.
AU  - Cruz-Hernandez, J. J.
AU  - Salgado-Fernandez. M.
AU  - Salud-Salvia, A.
AU  - Garcia-Carbonero, R.
AU  - Massuti-Sureda, B.
AU  - Vicente-Conesa, M. A. 
AU  - Lloansi-Vila, A.
PY  - 2021
DO  - 10.1016/j.annonc.2021.08.976
SN  - 0923-7534
UR  - https://hdl.handle.net/10668/25694
T2  - Annals of oncology
AB  - Tumor - tissue biopsy is the standard of care (SOC) to assess  RAS  & BRAF ms in mCRC pts. However, the analysis of circulating cfDNA has the advantage of evidencing genetic  tumor heterogeneity. We explored the occurrence of KRAS, NRAS and BRAF...
LA  - en
PB  - Elsevier
KW  - Humans
KW  - Cell-Free Nucleic Acids
KW  - Standard of Care
KW  - Proto-Oncogene Proteins B-raf
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Biopsy
KW  - Colorectal Neoplasms
TI  - Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)
TY  - conference output
VL  - 32
ER  -